Literature DB >> 20448239

Persistent symptomatic intra-abdominal collection after catheter removal for PD-related peritonitis.

Cheuk-Chun Szeto1, Bonnie Ching-Ha Kwan, Kai-Ming Chow, Wing-Fai Pang, Vickie Wai-Ki Kwong, Chi-Bon Leung, Philip Kam-Tao Li.   

Abstract

BACKGROUND: Peritoneal dialysis (PD) patients with severe peritonitis require catheter removal. It is often assumed that this approach, together with antibiotics, would eradicate the infection; however, some patients continue to have problems despite catheter removal.
METHOD: We reviewed 30 consecutive PD patients in our center from 1997 to 2008 with recurrent loculated peritoneal collection after catheter removal for severe peritonitis.
RESULTS: Of the 1928 episodes of peritonitis that occurred in 702 patients during the study period, 11.1% required catheter removal and 1.6% developed recurrent peritoneal collection that required percutaneous drainage. Median time to diagnosis of intra-abdominal collection was 12 days after catheter removal (interquartile range 7 - 61 days). In 25 patients (83.3%), aspirate of the abdominal collection was culture negative. In 17 patients (56.7%), the abdominal collection was recurrent and required repeated percutaneous aspiration. Only 3 patients had successful reinsertion of the peritoneal catheter but all had reduced small solute clearance after returning to PD.
CONCLUSION: A small but not negligible proportion of patients with PD-related peritonitis develop recurrent intra-abdominal collection that requires percutaneous drainage after catheter removal. The chance of a successful return to PD is very low in this group of patients. Direct conversion to long-term hemodialysis may avoid unnecessary attempts at peritoneal catheter reinsertion.

Entities:  

Mesh:

Year:  2010        PMID: 20448239     DOI: 10.3747/pdi.2009.00185

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  7 in total

1.  Towards standardized reporting in studies of encapsulating peritoneal sclerosis.

Authors:  Mark Lambie; Niko Braun; Simon J Davies
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

Review 2.  Peritoneal dialysis-related infections recommendations: 2016 update. What is new?

Authors:  Vassilios Liakopoulos; Olga Nikitidou; Theofanis Kalathas; Stefanos Roumeliotis; Marios Salmas; Theodoros Eleftheriadis
Journal:  Int Urol Nephrol       Date:  2017-06-01       Impact factor: 2.370

3.  Risk factors for drainage-requiring ascites after refractory peritonitis in peritoneal dialysis patients.

Authors:  Cheng-Chia Lee; Kun-Hua Tu; Hsiao-Hui Chen; Ming-Yang Chang; Cheng-Chieh Hung
Journal:  Int Urol Nephrol       Date:  2016-08-05       Impact factor: 2.370

4.  Persistent sterile peritoneal inflammation after catheter removal for refractory bacterial peritonitis predicts full-blown encapsulating peritoneal sclerosis.

Authors:  Yuk-Yi Wong; Ping-Nam Wong; Siu-Ka Mak; Shuk-Fan Chan; Yuen-Yi Cheuk; Lo-Yi Ho; Kin-Yee Lo; Man-Wai Lo; Kwok-Chi Lo; Gensy Mei-Wah Tong; Andrew Kui-Man Wong
Journal:  Perit Dial Int       Date:  2013-08-01       Impact factor: 1.756

5.  An intra-abdominal abscess or "rind" as a consequence of peritoneal dialysis-associated pseudomonas peritonitis.

Authors:  R Michael Culpepper; Sarah Gore; Gregory W Rutecki
Journal:  Clin Nephrol Case Stud       Date:  2013-02-26

Review 6.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

7.  Clinical risk factors and outcomes of massive ascites accumulation after discontinuation of peritoneal dialysis.

Authors:  Ming-Shan Chang; Nai-Ching Chen; Chih-Yang Hsu; Chien-Wei Huang; Po-Tsang Lee; Kang-Ju Chou; Hua-Chang Fang; Chien-Liang Chen
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.